Epstein-Barr Virus-Associated Lymphoproliferative Disorders in Immunocompromised Individuals

1991 ◽  
pp. 329-380 ◽  
Author(s):  
J. Alero Thomas ◽  
Martin J. Allday ◽  
Dorothy H. Crawford
Keyword(s):  
Epstein Barr Virus ◽  
Lymphoproliferative Disorders ◽  
Barr Virus ◽  
Epstein Barr

Three Rwandan Children With Massive Splenomegaly and Epstein-Barr Virus–associated Lymphoproliferative Disorders

2016 ◽  
Vol 38 (5) ◽  
pp. e158-e161 ◽  
Author(s):  
DeAnna Friedman-Klabanoff ◽  
Allison Ball ◽  
Samuel Rutare ◽  
Natalie McCall ◽  
Douglas P. Blackall
Keyword(s):  
Epstein Barr Virus ◽  
Lymphoproliferative Disorders ◽  
Massive Splenomegaly ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders

2019 ◽  
Vol 6 ◽  
Author(s):  
Sanjay de Mel ◽  
Joshua Zhi-Chien Tan ◽  
Anand D. Jeyasekharan ◽  
Wee-Joo Chng ◽  
Siok-Bian Ng
Keyword(s):  
Epstein Barr Virus ◽  
Lymphoproliferative Disorders ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation

Blood ◽  
1988 ◽  
Vol 71 (5) ◽  
pp. 1234-1243 ◽  
Author(s):  
RS Shapiro ◽  
K McClain ◽  
G Frizzera ◽  
KJ Gajl-Peczalska ◽  
JH Kersey ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
B Cell ◽  
Marrow Transplantation ◽  
Cytogenetic Analysis ◽  
Epstein Barr Virus ◽  
Lymphoproliferative Disorders ◽  
Solid Organ ◽  
Barr Virus ◽  
Epstein Barr

Abstract B cell lymphoproliferative disorders (BLPD) developed in eight patients following bone marrow transplantation (BMT) for leukemia (five patients) or immunodeficiency (three patients). Recipients of T depleted marrow from a mismatched donor were at particularly high risk of this complication. Six of 25 (24%) recipients of mismatched T depleted bone marrow developed BLPD. In contrast, none of 47 matched T depleted transplants, one of ten (10%) who received non-depleted marrow from an unrelated donor, and only one of 424 matched non-depleted transplants were associated with BLPD. Epstein-Barr virus (EBV) specific serology and DNA hybridization studies demonstrating five to 50 copies of EBV genome/cell in involved tissues implicate this virus as an associated etiologic agent. Restriction fragment length polymorphism (RFLP) and cytogenetic analysis of involved tissue demonstrated donor origin (five of seven) or host origin (two of seven). Histologic appearance was similar to EBV-induced polymorphic B cell proliferations described following solid organ transplantation, or which occur de novo in primary immunodeficiency. Six of seven patients with adequate tissue available for study were found to have monoclonal proliferations by: in situ immunofluorescence (six of seven), and/or immunoglobulin gene rearrangement, (four of six). Cytogenetic analysis of involved tissues from four patients showed a normal karyotype, whereas two had multiple clonal chromosomal abnormalities. Seven patients died despite aggressive attempts at therapy with combinations of antiviral, immunologic, and chemotherapeutic agents.

scholarly journals Epstein-Barr virus–associated lymphoproliferative disorders

2007 ◽  
Vol 38 (9) ◽  
pp. 1293-1304 ◽  
Author(s):  
Sherif A. Rezk ◽  
Lawrence M. Weiss
Keyword(s):  
Epstein Barr Virus ◽  
Lymphoproliferative Disorders ◽  
Barr Virus ◽  
Epstein Barr

Epstein–Barr virus associated CNS lymphoproliferative disorder after long-term immunosuppression

2019 ◽  
pp. practneurol-2019-002356 ◽  
Author(s):  
Andrew Lee ◽  
Leslie R Bridges ◽  
Mark Lloyd ◽  
Robert Barker ◽  
Damian R Wren ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Lymphoproliferative Disorders ◽  
Postmortem Brain ◽  
Barr Virus ◽  
Epstein Barr ◽  
High Index Of Suspicion ◽  
Immunomodulatory Therapies

The incidence of Epstein–Barr virus (EBV)associated lymphoproliferative disorders has increased with greater use of immunomodulatory therapies. We present a woman who developed subacute cognitive decline and unilateral weakness while taking long-term mycophenolate mofetil for granulomatosis with polyangiitis; her postmortem brain histopathology confirmed an EBV-driven lymphoproliferative disorder. Clinicians must have a high index of suspicion for EBV-driven lymphoma in people taking long-term immunosuppression who develop new neurological problems. We review the role of mycophenolate mofetil in EBV-driven lymphoproliferative disorders, and discuss checking EBV status in all patients starting immunosuppression and in older people already taking immunosuppression.

Sign in / Sign up

Export Citation Format

Share Document